[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549636":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":33,"responsibleParty":55,"collaborators":22,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":22,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":22,"enrollmentInfo":66,"targetDuration":22,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":22,"overallStatus":36,"whyStopped":22,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Jonsson Comprehensive Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm I","EXPERIMENTAL","MRI or CT-guided SBRT will be delivered in the pre-operative setting. Patients will receive 5.0-6.0 Gy x 5 fractions delivered daily.",[13],"Radiation: Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy","stereotactic body radiation therapy (SBRT) administered over 5 days x 5.0 - 6.0 Gy for patients with abdominopelvic sarcomas.",[9],[21],"Pre-operative stereotactic body radiation therapy (SBRT)",null,[24,29],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Christy Palodichuk","CONTACT","3107942971","cpalodichuk@mednet.ucla.edu",{"name":30,"role":26,"phone":31,"phoneExt":22,"email":32},"Vincent Basehart","3102678954","vbasehart@mednet.ucla.edu",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"UCLA \u002F Jonsson Comprehensive Cancer Center","RECRUITING","Los Angeles","California","90095","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-118.24368,34.05223,{"lat":46,"lon":45},[49,50,52],{"name":30,"role":26,"phone":31,"phoneExt":22,"email":32},{"name":51,"role":26,"phone":27,"phoneExt":22,"email":28},"Christine Palodichuk",{"name":53,"role":54,"phone":22,"phoneExt":22,"email":22},"Vishruth Reddy, MD","PRINCIPAL_INVESTIGATOR",{"type":56,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100549636","phase-2-study-of-magnetic-resonance-image-and-computed-tomography-guided-stereotactic-body-radiation-therapy-for-abdominopelvic-sarcomas-mars-trial-100549636",false,"NCT06436612","Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)","Phase II Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)","Inclusion Criteria:\n\n* Histologically confirmed sarcoma\n* Primary or recurrent disease involving the abdomen or pelvis\n* Resectable primary lesion\n* Age ≥ 12 years old\n* Karnofsky performance status (KPS) ≥ 70 or Eastern Cooperative Oncology Group (ECOG) 0-2\n* If a woman is of childbearing potential, a negative serum or urine pregnancy test must be documented\n\nExclusion Criteria:\n\n* Active treatment of a separate malignancy\n* History of prior irradiation to the area targeted for treatment","ALL","12 Years",{"count":67,"type":68},20,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","Recent advances in radiation treatment have allowed for higher doses per treatment to be delivered safely. This study plans to use an MRI-guided linear accelerator to deliver the radiation treatment to ensure that the radiation dose is administered to the cancerous tumor, not the vital body organs.\n\nPotential participants with a sarcoma diagnosis will be referred to Radiation Oncology during this study. If the participant is interested in participating in this study, s\u002Fhe receives radiation treatment daily for 5 consecutive days except for weekends and holidays. Within 12 weeks of completing the radiation therapy, the participant will have the primary tumor surgically removed. The radiation oncology team will follow the patients for 5 years after completing radiation therapy.",[74],"Abdominopelvic Sarcomas","2026-06-03",{"date":77,"type":78},"2026-06-05","ACTUAL",{"date":80,"type":78},"2024-05-30",{"date":82,"type":68},"2028-05-26",{"name":5,"class":6},1]